Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?
Saved in:
| Title: | Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma? |
|---|---|
| Authors: | Liu MA; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 675 N Saint Clair St., Ste 20-150, Chicago, IL, 60611, USA. Michael.liu1@northwestern.edu., Miyazaki K; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 675 N Saint Clair St., Ste 20-150, Chicago, IL, 60611, USA., Runcie K; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA., Cash H; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 675 N Saint Clair St., Ste 20-150, Chicago, IL, 60611, USA., Meng L; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. |
| Source: | Targeted oncology [Target Oncol] 2026 May 31. Date of Electronic Publication: 2026 May 31. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
